P.3.009 Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs

Albert, Umberto; Maina, Giuseppe; Forner, Federica; Bogetto, Filippo

doi:10.1016/s0924-977x(03)92129-8

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antipsychotics’ side effects, mainly the metabolic ones [8], however, limit this option. The second strategy consists of sequentially adding CBT; the efficacy of this strategy is suggested by open-label reports [9,10,11,12,13,14] and a single randomized, controlled trial [15]. …”

Section: Tablementioning

confidence: 99%

Effectiveness of Cognitive-Behavioral Therapy Addition to Pharmacotherapy in Resistant Obsessive-Compulsive Disorder: A Multicenter Study

Albert

Aguglia

Bogetto

et al. 2012

Psychother Psychosom

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 99%

Effectiveness of Cognitive-Behavioral Therapy Addition to Pharmacotherapy in Resistant Obsessive-Compulsive Disorder: A Multicenter Study

Albert

Aguglia

Bogetto

et al. 2012

Psychother Psychosom

View full text Add to dashboard Cite

“…104 Individuals with OCD treated with therapy have been found to maintain their gains fol-lowing discontinuation of treatment, while up to 80% of patients treated pharmacologically relapse upon treatment discontinuation. 105 With the exception of Albert and colleages 106 though, no well designed study to date has demonstrated an improvement in Y-BOCS scores using behavioral therapy in patients partially responsive to SRI monotherapy. While an argument can be made for the use of behavioral therapy in addition to pharmacotherapy, the literature to date provides insufficient evidence to guide clinical practice.…”

Section: Psychotherapy For Treatment Of Obsessive-compulsive Disordermentioning

confidence: 99%

A Review of the Treatment for Refractory Obsessive-Compulsive Disorder: From Medicine to Deep Brain Stimulation

Husted

Shapira²

2004

CNS spectr.

View full text Add to dashboard Cite

This article provides an overview of the etiology, epidemiology, and first-line treatment options for obsessive-compulsive disorder (OCD). The subject of treatment-resistant and treatment-refractory OCD is then discussed, including a definition of these often-debated terms, and the latest treatment options delineated. This includes a review of the latest research concerning the pharmacological agents that have been studied as monotherapy or augmenting agents for the treatment of OCD, the use of experimental medications and procedures, treatment with reversible, minimally invasive procedures, such as vagal nerve stimulation and transcranial magnetic stimulation, invasive but the potentially reversible deep brain stimulation, and irreversible lesioning with ablative psychosurgery. A discussion of the role of psychotherapy in the treatment of OCD is also included.

show abstract

“…Provision of adequate psychotherapy for OCD, known as exposure and response prevention therapy (E/RP), is a safe and effective intervention, which may work as well, or better than medication alone, and may also augment partial response to SRIs [36]. Cognitive-behavioural therapy (CBT) is the preferred intervention for children and adolescents, and for patients with milder OCD [8].…”

Section: Establishment Of Treatment-resistance and The Role Of Psychomentioning

confidence: 99%

Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder

Walsh¹,

McDougle

2004

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

First-line treatment for obsessive-compulsive disorder (OCD) has been well-established for over a decade, although newer medications, such as citalopram and venlafaxine, have emerged to take a place among the older, more established serotonin re-uptake inhibitors (SRIs). Unfortunately, as many as 50% of all patients with OCD will have symptoms refractory to a single medication treatment trial, and a smaller percentage will remain refractory after two or more trials. The optimal dosage and duration for first-line trials have been established. Many strategies exist for patients who do not respond to first- or second-line medication trials, including behavioural therapy, switching to newer SRIs, and augmentation with additional medications. This review will focus on medication strategies for augmenting SRI treatment response in OCD treatment, including neuroleptic and serotonergic agents. Future investigations should include more controlled studies and investigate medications that are less likely to trigger extrapyramidal symptoms, diabetes mellitus and weight gain.

show abstract

P.3.009 Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs

Cited by 7 publications

References 0 publications

Effectiveness of Cognitive-Behavioral Therapy Addition to Pharmacotherapy in Resistant Obsessive-Compulsive Disorder: A Multicenter Study

Effectiveness of Cognitive-Behavioral Therapy Addition to Pharmacotherapy in Resistant Obsessive-Compulsive Disorder: A Multicenter Study

A Review of the Treatment for Refractory Obsessive-Compulsive Disorder: From Medicine to Deep Brain Stimulation

Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder

Contact Info

Product

Resources

About